LeukoPlax

**LeukoPlax** is an investigational 3D-printed local drug delivery product being developed by CADRx Precision Medicines for **oral leukoplakia**, a premalignant oral lesion with risk of progression to oral cancer. The platform uses **biocompatible, biodegradable, mucoadhesive dosage forms** engineered for **directional unidirectional topical delivery** of **very low doses of synergistic repurposed FDA-approved drugs** directly to the lesion site, with tunable pharmacokinetics intended to improve local exposure while minimizing systemic toxicity. Based on currently available public information, LeukoPlax is best characterized as a **drug-device combination style precision pharmaceutical platform/formulation** for oral cancer prevention, but the specific active ingredients and molecular targets have not been publicly disclosed.

Brand names

LeukoPlax

Other names

LeukoPlax